Document is current
Any future updates will be listed below
-
Authors
Patel, Parth S.
Uppuluri, Aditya
Oydanich, Marko
Langer, Paul D.
Zarbin, Marco A.
Bhagat, Neelakshi https://orcid.org/0000-0003-2187-3145
- License Information
-
More Information
Article History
Received: 3 June 2022
Accepted: 26 August 2022
First Online: 3 September 2022
Declarations
:
: The following authors state their respective competing interests: Marco A. Zarbin, MD, PhD is a consultant for Genentech/Roche, Novartis Pharma AG, Frequency Therapeutics, Iveric Bio, Ophthotech, Perfuse Therapeutics, Selphagy, Iduna, and Life Biosciences. He is a stockholder for Frequency Therapeutics, Iveric Bio, and NVasc. He is Co-Founder of NVasc. Paul D. Langer, MD is a consultant for Matrix Surgical, USA. None of the following authors have any proprietary interests or conflicts of interest related to this submission: Parth S Patel, Aditya Uppuluri, Marko Oydanich, Neelakshi Bhagat
: This is a retrospective observational study. The Rutgers Biomedical Health Sciences IRB has confirmed that no ethical approval is required as the data is sourced from a national de-identified database.
